Pamiparib in combination with surufatinib in patients with platinum-resistant ovarian cancer who received prior PARP inhibitors: a multicenter, single-arm, phase Ib/II trial (POST-PARPi Trial)
Dr. Ammar Alshehri
Speaker
Menu